These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30133998)

  • 41. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
    Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
    Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response of severe psoriasis to infliximab.
    Mang R; Stege H; Ruzicka T; Krutmann J
    Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
    [No Abstract]   [Full Text] [Related]  

  • 43. Secukinumab in multi-failure psoriatic patients: the last hope?
    Magnano M; Loi C; Patrizi A; Sgubbi P; Balestri R; Rech G; Tasin L; Girardelli CR; Conti A; Odorici G; Campanati A; Offidani AM; Bardazzi F
    J Dermatolog Treat; 2018 Sep; 29(6):583-585. PubMed ID: 29334270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
    Nast A; Spuls PI; van der Kraaij G; Gisondi P; Paul C; Ormerod AD; Saiag P; Smith CH; Dauden E; de Jong EM; Feist E; Jobling R; Maccarone M; Mrowietz U; Papp KA; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Dressler C
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1951-1963. PubMed ID: 28895202
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
    Campa M; Menter A
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1337-1344. PubMed ID: 27687859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-IL-23 Phase II Data for Psoriasis: A Review.
    Beroukhim K; Danesh MJ; Nguyen C; Austin A; Koo J; Levin E
    J Drugs Dermatol; 2015 Oct; 14(10):1093-6. PubMed ID: 26461819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complete response of secukinumab in palmoplantar psoriasis.
    Rocamora V; Garcías-Ladaria J
    Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.
    Brunasso AM; Puntoni M; Delfino C; Massone C
    Eur J Dermatol; 2012; 22(1):133-5. PubMed ID: 22134100
    [No Abstract]   [Full Text] [Related]  

  • 50. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
    Blauvelt A; Reich K; Warren RB; Szepietowski JC; Sigurgeirsson B; Tyring SK; Messina I; Bhosekar V; Oliver J; Papavassilis C; Frueh J; Langley RGB
    Br J Dermatol; 2017 Sep; 177(3):879-881. PubMed ID: 28498514
    [No Abstract]   [Full Text] [Related]  

  • 51. Impetigo herpetiformis with IL-36RN mutation successfully treated with secukinumab.
    Kinoshita M; Ogawa Y; Takeichi T; Okamoto T; Osada A; Shimada S; Sugiura K; Akiyama M; Kawamura T; Tsukamoto K
    Eur J Dermatol; 2018 Jun; 28(3):381-382. PubMed ID: 30105995
    [No Abstract]   [Full Text] [Related]  

  • 52. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
    Strober B; Gottlieb AB; Sherif B; Mollon P; Gilloteau I; McLeod L; Fox T; Mordin M; Gnanasakthy A; Papavassilis C; Lebwohl MG
    J Am Acad Dermatol; 2017 Apr; 76(4):655-661. PubMed ID: 28087133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
    Mrowietz U; Leonardi CL; Girolomoni G; Toth D; Morita A; Balki SA; Szepietowski JC; Regnault P; Thurston H; Papavassilis C;
    J Am Acad Dermatol; 2015 Jul; 73(1):27-36.e1. PubMed ID: 25982539
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful patch testing of a patient receiving anti-interleukin-17 therapy with secukinumab: a case report.
    Hamann D; Zirwas M
    Contact Dermatitis; 2017 Jun; 76(6):378-379. PubMed ID: 28497628
    [No Abstract]   [Full Text] [Related]  

  • 56. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword.
    Gottlieb AB
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570
    [No Abstract]   [Full Text] [Related]  

  • 58. Excessive hair growth in a patient with psoriatic erythroderma following secukinumab administration.
    Mashima E; Sawada Y; Yamaguchi T; Yoshioka H; Ohmori S; Haruyama S; Okada E; Nakamura M
    Eur J Dermatol; 2018 Aug; 28(4):539-540. PubMed ID: 30325327
    [No Abstract]   [Full Text] [Related]  

  • 59. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
    Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
    J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
    [No Abstract]   [Full Text] [Related]  

  • 60. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.